Evidence map›Paper›PMID 40366475›Full record

ArticleJournal of neurology2025

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.

Elena Rossini, Vincenzo Di Stefano, Raffaele Iorio, Francesco Habetswallner, Michelangelo Maestri, Claudia Vinciguerra, Elena Maria Pennisi, Giuseppe Di Martino, Nicasio Rini, Silvia Falso and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Italian recommendations for the diagnosis and treatment of myasthenia gravis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Elena RossiniDepartment of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, SAPIENZA University of Rome, Sant'Andrea Hospital, Via Di Grottarossa 1035-1039, 00189, Rome, Italy. elena.rossini@uniroma1.it.ORCID http://orcid.org/0009-0002-7862-6743
Vincenzo Di StefanoBiomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo, Palermo, Italy.
Raffaele IorioDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Francesco HabetswallnerUOC Neurophysiopathology, AORN Cardarelli, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Michelangelo MaestriDepartment of Clinical & Experimental Medicine, Neurology Unit, University of Pisa, 56126, Pisa, Italy.
Claudia VinciguerraDepartment of Medicine Surgery and Dentistry, Neurology Unit, University Hospital "San Giovanni Di Dio E Ruggi d'Aragona", Scuola Medica Salernitana", Neuroscience Section, Salerno, Italy.
Elena Maria PennisiNeuromuscular Diseases Center, Neurology Unit, San Filippo Neri Hospital, Rome, Italy.
Giuseppe Di MartinoBiomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo, Palermo, Italy.
Nicasio RiniBiomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo, Palermo, Italy.
Silvia FalsoDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Sofia MariniDepartment of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.
Dario RicciardiUOC Neurophysiopathology, AORN Cardarelli, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Melania GuidaDepartment of Clinical & Experimental Medicine, Neurology Unit, University of Pisa, 56126, Pisa, Italy.
Stefania MorinoNeuromuscular and Rare Disease Centre, Neurology Unit, Sant'Andrea Hospital, Rome, Italy.
Matteo GaribaldiDepartment of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, SAPIENZA University of Rome, Sant'Andrea Hospital, Via Di Grottarossa 1035-1039, 00189, Rome, Italy.
Luca LeonardiNeuromuscular and Rare Disease Centre, Neurology Unit, Sant'Andrea Hospital, Rome, Italy.
Demetrio MarandoDepartment of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, SAPIENZA University of Rome, Sant'Andrea Hospital, Via Di Grottarossa 1035-1039, 00189, Rome, Italy.
Laura TufanoDepartment of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, SAPIENZA University of Rome, Sant'Andrea Hospital, Via Di Grottarossa 1035-1039, 00189, Rome, Italy.
Giovanni Antonini *Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, SAPIENZA University of Rome, Sant'Andrea Hospital, Via Di Grottarossa 1035-1039, 00189, Rome, Italy.
Laura Fionda *Neuromuscular and Rare Disease Centre, Neurology Unit, Sant'Andrea Hospital, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRavulizumab, a monoclonal antibody targeting C5, was recently approved for the treatment of anti-AChR positive generalized myasthenia gravis (gMG) patients. The objective of this study is to present the Italian multicenter real-world experience evaluating the safety and efficacy of ravulizumab in gMG within the context of the Expanded Early Access Program (EAP).

methodsWe conducted a retrospective study in 7 gMG referral centres in Italy. Demographic and clinical characteristics were recorded at baseline and during follow-up through clinical scale changes including Myasthenia Gravis-Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Composite (MGC). Frequency of minimal symptom expression (MSE) and changes in concomitant medications were also evaluated.

resultsTwenty-four gMG patients (10/24 females) aged between 24 and 82 years (Median 60.5, IQR 52.5-67.5), were included. Fifteen patients had undergone thymectomy, and 14 had a thymoma. Median follow-up duration was 26 weeks (range 10-74, IQR 26-42). MG-ADL and QMG scores showed a significant decrease with respect to baseline (p < 0.001). MSE was achieved by 37.5% patients at the last available follow-up. Tapering of prednisone daily dosage was possible in 76% of patients. Thymoma was significantly associated with QMG score reduction and the frequency of QMG responders at week 2 (p = 0.03). Three patients discontinued treatment. One patient experienced a myasthenic exacerbation and needed rescue therapy. Infectious adverse events were reported in 5/24 patients, and a Stevens-Johnson syndrome in one patient.

conclusionsReal-world data confirm the effectiveness, safety, and prednisone-sparing effect of ravulizumab in patients with gMG, especially in those with thymoma.

Indexed as

Antibodies, Monoclonal, HumanizedMyasthenia GravisActivities of Daily LivingAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansItalyMaleMiddle AgedRetrospective StudiesTreatment OutcomeYoung AdultAntibodies, Monoclonal, HumanizedComplement inhibitor therapyMyasthenia GravisRavulizumabReal life study

Identifiers

PMID40366475
PMCPMC12078421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.